New Agreement Marks LifeCore’s Thirteenth Late-State Program to Generate Revenue
Lifecore Biomedical, Inc., a fully integrated injectables CDMO, has signed a new agreement to transfer a commercially marketed product to the company’s pipeline. Under the terms of the agreement, Lifecore will perform technical transfer services to support commercial production of an injectable drug product. The new agreement with a global pharmaceutical company marks Lifecore’s seventh late-stage commercial program and the eleventh program added to its pipeline in 2026. This program is expected to generate commercial revenues in 2028.
“This product’s unique formulation and manufacturing complexity align directly with Lifecore’s strong technical expertise in high-viscosity, complex products,” says Paul Josephs, CEO of Lifecore.
He adds that this opportunity reflects the “solution-driven organization” that LifeCore is looking to build. “A critical component of our growth strategy is our revamped commercial approach, focused on adding high-impact programs to our development pipeline. The addition of this new program provides clear evidence that this strategy is working.”
This program brings LifeCore’s late-stage pipeline to thirteen that have the potential to generate commercial revenues by the end of 2028, says Josephs.
For more information, visit LifeCore.com.
Total Page Views: 218
